## Core Concept
Gp2b3A inhibitors, also known as **glycoprotein IIb/IIIa inhibitors**, are a class of antiplatelet drugs that prevent platelet aggregation by blocking the **fibrinogen binding site** on the glycoprotein IIb/IIIa receptor on the platelet surface. This class of drugs is commonly used in acute coronary syndromes and during **percutaneous coronary interventions (PCI)**.

## Why the Correct Answer is Right
The correct answer, , is a Gp2b3A inhibitor because it works by specifically inhibiting the glycoprotein IIb/IIIa receptor. This mechanism effectively prevents platelet aggregation, which is crucial in the formation of arterial thrombi.

## Why Each Wrong Option is Incorrect
* **Option A:** - This option is actually a Gp2b3A inhibitor, as it blocks the glycoprotein IIb/IIIa receptor.
* **Option B:** - Similarly, this option is also a Gp2b3A inhibitor.
* **Option C:** - This is another Gp2b3A inhibitor.

## Clinical Pearl / High-Yield Fact
A key point to remember is that **abciximab** is a **monoclonal antibody** against the Gp2b3A receptor, while **eptifibatide** and **tirofiban** are **small molecule inhibitors**. This distinction is important for understanding their pharmacokinetics and clinical use.

## Correct Answer Line
**Correct Answer: D.**